$9.76
0.67% today
Nasdaq, Apr 02, 09:16 pm CET
ISIN
US98401F1057
Symbol
XNCR

Xencor, Inc. Stock price

$9.69
-4.77 32.99% 1M
-9.95 50.66% 6M
-13.29 57.83% YTD
-12.23 55.79% 1Y
-18.85 66.05% 3Y
-18.07 65.09% 5Y
-5.47 36.08% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.95 8.93%
ISIN
US98401F1057
Symbol
XNCR
Sector
Industry

Key metrics

Market capitalization $682.78m
Enterprise Value $413.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.74
P/S ratio (TTM) P/S ratio 6.18
P/B ratio (TTM) P/B ratio 1.00
Revenue growth (TTM) Revenue growth -36.72%
Revenue (TTM) Revenue $110.49m
EBIT (operating result TTM) EBIT $-178.41m
Free Cash Flow (TTM) Free Cash Flow $-208.29m
Cash position $497.78m
EPS (TTM) EPS $-3.64
P/E forward negative
P/S forward 6.46
EV/Sales forward 3.91
Short interest 14.12%
Show more

Is Xencor, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Xencor, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Xencor, Inc. forecast:

10x Buy
91%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Xencor, Inc. forecast:

Buy
91%
Sell
9%

Financial data from Xencor, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
110 110
37% 37%
100%
- Direct Costs 12 12
5% 5%
11%
98 98
40% 40%
89%
- Selling and Administrative Expenses 37 37
22% 22%
33%
- Research and Development Expense 228 228
10% 10%
206%
-166 -166
38% 38%
-151%
- Depreciation and Amortization 12 12
5% 5%
11%
EBIT (Operating Income) EBIT -178 -178
35% 35%
-161%
Net Profit -233 -233
75% 75%
-211%

In millions USD.

Don't miss a Thing! We will send you all news about Xencor, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xencor, Inc. Stock News

Neutral
Business Wire
20 days ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies an...
Neutral
Business Wire
about one month ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided clinical updates and priorities for 2025. “In 2024, we began rebalancing our pipeline to focus on ...
Positive
Market Watch
about one month ago
The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries.
More Xencor, Inc. News

Company Profile

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Head office United States
CEO Bassil Dahiyat
Employees 250
Founded 1997
Website www.xencor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today